vs

Side-by-side financial comparison of Baxter International (BAX) and Invesco (IVZ). Click either name above to swap in a different company.

Baxter International is the larger business by last-quarter revenue ($2.7B vs $1.7B, roughly 1.6× Invesco). Baxter International runs the higher net margin — -0.6% vs -58.9%, a 58.3% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs 3.0%). Invesco produced more free cash flow last quarter ($432.2M vs $76.0M). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs -15.8%).

Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

BAX vs IVZ — Head-to-Head

Bigger by revenue
BAX
BAX
1.6× larger
BAX
$2.7B
$1.7B
IVZ
Growing faster (revenue YoY)
IVZ
IVZ
+3.2% gap
IVZ
6.2%
3.0%
BAX
Higher net margin
BAX
BAX
58.3% more per $
BAX
-0.6%
-58.9%
IVZ
More free cash flow
IVZ
IVZ
$356.2M more FCF
IVZ
$432.2M
$76.0M
BAX
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
-15.8%
BAX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BAX
BAX
IVZ
IVZ
Revenue
$2.7B
$1.7B
Net Profit
$-15.0M
$-995.9M
Gross Margin
33.0%
Operating Margin
2.4%
-86.2%
Net Margin
-0.6%
-58.9%
Revenue YoY
3.0%
6.2%
Net Profit YoY
-575.8%
EPS (diluted)
$-0.03
$-2.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BAX
BAX
IVZ
IVZ
Q1 26
$2.7B
Q4 25
$3.0B
$1.7B
Q3 25
$2.8B
$1.6B
Q2 25
$2.8B
$1.5B
Q1 25
$2.6B
$1.5B
Q4 24
$533.0M
$1.6B
Q3 24
$2.7B
$1.5B
Q2 24
$3.8B
$1.5B
Net Profit
BAX
BAX
IVZ
IVZ
Q1 26
$-15.0M
Q4 25
$-1.1B
$-995.9M
Q3 25
$-46.0M
$356.4M
Q2 25
$91.0M
$197.4M
Q1 25
$126.0M
$171.1M
Q4 24
$-512.0M
$209.3M
Q3 24
$140.0M
$55.0M
Q2 24
$-314.0M
$132.2M
Gross Margin
BAX
BAX
IVZ
IVZ
Q1 26
33.0%
Q4 25
19.4%
Q3 25
33.5%
Q2 25
35.3%
Q1 25
32.8%
Q4 24
25.0%
Q3 24
38.3%
Q2 24
37.5%
Operating Margin
BAX
BAX
IVZ
IVZ
Q1 26
2.4%
Q4 25
-24.5%
-86.2%
Q3 25
6.1%
16.5%
Q2 25
6.8%
14.1%
Q1 25
2.2%
18.1%
Q4 24
-25.5%
19.6%
Q3 24
5.7%
6.6%
Q2 24
-5.0%
13.9%
Net Margin
BAX
BAX
IVZ
IVZ
Q1 26
-0.6%
Q4 25
-37.9%
-58.9%
Q3 25
-1.6%
21.7%
Q2 25
3.2%
13.0%
Q1 25
4.8%
11.2%
Q4 24
-96.1%
13.1%
Q3 24
5.2%
3.6%
Q2 24
-8.2%
8.9%
EPS (diluted)
BAX
BAX
IVZ
IVZ
Q1 26
$-0.03
Q4 25
$-2.21
$-2.61
Q3 25
$-0.09
$0.66
Q2 25
$0.18
$-0.03
Q1 25
$0.25
$0.38
Q4 24
$-0.99
$0.46
Q3 24
$0.27
$0.12
Q2 24
$-0.62
$0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BAX
BAX
IVZ
IVZ
Cash + ST InvestmentsLiquidity on hand
$1.0B
Total DebtLower is stronger
$1.8B
Stockholders' EquityBook value
$12.2B
Total Assets
$27.1B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
$2.0B
$1.0B
Q3 25
$1.7B
$973.1M
Q2 25
$1.7B
$922.7M
Q1 25
$2.3B
$821.7M
Q4 24
$1.8B
$986.5M
Q3 24
$1.4B
$1.0B
Q2 24
$2.1B
$878.5M
Total Debt
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
$9.5B
$1.8B
Q3 25
$1.6B
Q2 25
$1.9B
Q1 25
$964.8M
Q4 24
$10.4B
$890.6M
Q3 24
$10.4B
$890.3M
Q2 24
$10.4B
$890.1M
Stockholders' Equity
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
$6.1B
$12.2B
Q3 25
$7.2B
$14.0B
Q2 25
$7.3B
$13.9B
Q1 25
$7.1B
$14.7B
Q4 24
$7.0B
$14.6B
Q3 24
$7.9B
$14.8B
Q2 24
$7.6B
$14.6B
Total Assets
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
$20.1B
$27.1B
Q3 25
$21.1B
$28.4B
Q2 25
$21.0B
$28.5B
Q1 25
$21.3B
$28.1B
Q4 24
$25.8B
$27.0B
Q3 24
$26.7B
$27.5B
Q2 24
$26.3B
$27.2B
Debt / Equity
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
1.55×
0.15×
Q3 25
0.12×
Q2 25
0.14×
Q1 25
0.07×
Q4 24
1.49×
0.06×
Q3 24
1.33×
0.06×
Q2 24
1.37×
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BAX
BAX
IVZ
IVZ
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$76.0M
$432.2M
FCF MarginFCF / Revenue
2.8%
25.5%
Capex IntensityCapex / Revenue
5.1%
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
$584.0M
$455.8M
Q3 25
$237.0M
$606.2M
Q2 25
$217.0M
$547.9M
Q1 25
$-193.0M
$-84.6M
Q4 24
$488.0M
$316.9M
Q3 24
$253.0M
$438.4M
Q2 24
$115.0M
$489.1M
Free Cash Flow
BAX
BAX
IVZ
IVZ
Q1 26
$76.0M
Q4 25
$432.2M
Q3 25
$586.4M
Q2 25
$530.4M
Q1 25
$-108.0M
Q4 24
$309.9M
Q3 24
$410.0M
Q2 24
$462.4M
FCF Margin
BAX
BAX
IVZ
IVZ
Q1 26
2.8%
Q4 25
25.5%
Q3 25
35.7%
Q2 25
35.0%
Q1 25
-7.1%
Q4 24
19.5%
Q3 24
27.1%
Q2 24
31.2%
Capex Intensity
BAX
BAX
IVZ
IVZ
Q1 26
5.1%
Q4 25
1.4%
Q3 25
1.2%
Q2 25
1.2%
Q1 25
1.5%
Q4 24
0.4%
Q3 24
1.9%
Q2 24
1.8%
Cash Conversion
BAX
BAX
IVZ
IVZ
Q1 26
Q4 25
Q3 25
1.70×
Q2 25
2.38×
2.78×
Q1 25
-1.53×
-0.49×
Q4 24
1.51×
Q3 24
1.81×
7.97×
Q2 24
3.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BAX
BAX

Segment breakdown not available.

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

Related Comparisons